Gen-Wealth Partners’s Novavax NVAX Stock Holding History

Gen-Wealth Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471	Hold	50	–	–	﹤0.01%	693
2026 Q1	$407	Hold	50	–	–	﹤0.01%	700
2025 Q4	$336	Hold	50	–	–	﹤0.01%	672
2025 Q3	$434	Buy	+50	New	+$389	﹤0.01%	660

Other funds holding NVAX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Gen-Wealth Partners's NVAX Position: Q2 2026 in Review

Gen-Wealth Partners held its Novavax (NVAX) position steady in Q2 2026 at 50 shares worth $471. The position accounts for ﹤0.01% of the portfolio, ranked #693.

Gen-Wealth Partners first reported a position in NVAX in Q3 2025 and has held it in 4 quarters since. 113 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Gen-Wealth Partners held 50 shares of Novavax worth $471 as of Q2 2026.
Gen-Wealth Partners left its Novavax share count unchanged in Q2 2026.
Novavax made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q2 2026, its #693 holding.
Gen-Wealth Partners first reported a position in Novavax in Q3 2025 and has held it in 4 quarters since.
113 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.